Drug Type Small molecule drug, Diagnostic radiopharmaceuticals |
Synonyms 11C-T-1650, [11C]-T1650 |
Target |
Action inhibitors, enhancers |
Mechanism PDE4D inhibitors(phosphodiesterase 4D inhibitors), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Depressive Disorder | Phase 2 | United States | 12 Mar 2019 | |
Cognition Disorders | Preclinical | United States | 26 Mar 2020 | |
Cognition Disorders | Preclinical | United States | 26 Mar 2020 |
Phase 1/2 | 3 | (Brain PET Scan With 11C-T-1650 and Blocking With BPN14770) | ktrvnvuxxu(sdpuzpdzin) = wgnguiuffg xkhxpckbbx (nzyielnfsf, 0.91) View more | - | 12 Feb 2021 | ||
(Whole Body PET Scan With Intravenous 11C-T-1650) | abtdmjuwiz(geqmpvyahw) = kcvemuiral rrgbihpodj (bjagxrgjgc, qipxrntgto - jasxfaxjyh) View more |